The association between corneal neovascularization and visual acuity: A systematic review

Acta Ophthalmologica

Volumn 91, Issue 1, 2013, Pages 12-19

  Bachmann, Bjoern ^a   Taylor, Rod S ^b   Cursiefen, Claus ^a,c  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b PENINSULA MEDICAL SCHOOL   (United Kingdom)

^c UNIVERSITY OF COLOGNE   (Germany)

Author keywords

antiangiogenic therapy; corneal neovascularization; haemangiogenesis; visual acuity

Indexed keywords

AGANIRSEN; BEVACIZUMAB; PLACEBO;

CORNEA NEOVASCULARIZATION; DISEASE ASSOCIATION; FOLLOW UP; HUMAN; MORPHOMETRICS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; SLIT LAMP; SYSTEMATIC REVIEW; VISUAL ACUITY;

ANGIOGENESIS INHIBITORS; CORNEAL NEOVASCULARIZATION; HUMANS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84873059955     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/j.1755-3768.2011.02312.x     Document Type: Review

References (27)

1. Bachmann B, Taylor RS, &, Cursiefen C, (2010): Corneal neovascularization as a risk factor for graft failure and rejection following keratoplasty: an evidence-based meta-analysis. Ophthalmology 117: 1300-1305.e7.
2. Bahar I, Kaiserman I, McAllum P, Rootman D, &, Slomovic A, (2008a): Subconjunctival bevacizumab injection for corneal neovascularization. Cornea 27: 142-147.
3. Bahar I, Kaiserman I, McAllum P, Rootman D, &, Slomovic A, (2008b): Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium. Curr Eye Res 33: 23-28.
4. Bock F, Onderka J, Dietrich T, Bachmann B, Kruse FE, Paschke M, Zahn G, &, Cursiefen C, (2007): Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci 48: 2545-2552.
5. Bock F, Konig Y, Kruse F, Baier M, &, Cursiefen C, (2008a): Bevacizumab (Avastin) eye drops inhibit corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 246: 281-284.
6. Bock F, Onderka J, Hos D, Horn F, Martus P, &, Cursiefen C, (2008b): Improved semiautomatic method for morphometry of angiogenesis and lymphangiogenesis in corneal flatmounts. Exp Eye Res 87: 462-470.
7. Cursiefen C, Wenkel H, Martus P, Langenbucher A, Nguyen NX, Seitz B, Kuchle M, &, Naumann GO, (2001): Impact of short-term versus long-term topical steroids on corneal neovascularization after non-high-risk keratoplasty. Graefes Arch Clin Exp Ophthalmol 239: 514-521.
8. Cursiefen C, Maruyama K, Jackson DG, Streilein JW, &, Kruse FE, (2006): Time course of angiogenesis and lymphangiogenesis after brief corneal inflammation. Cornea 25: 443-447.
9. Cursiefen C, Bock F, Horn FK, et al., (2009): GS-101 antisense oligonucleotide eye drops inhibit corneal neovascularization: interim results of a randomized phase II trial. Ophthalmology 116: 1630-1637.
10. Dastjerdi MH, Al-Arfaj KM, Nallasamy N, Hamrah P, Jurkunas UV, Pineda R II, Pavan-Langston D, &, Dana R, (2009): Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study. Arch Ophthalmol 127: 381-389.
11. Doctor PP, Bhat PV, &, Foster CS, (2008): Subconjunctival bevacizumab for corneal neovascularization. Cornea 27: 992-995.
12. Habot-Wilner Z, Barequet IS, Ivanir Y, Moisseiev J, &, Rosner M, (2010): The inhibitory effect of different concentrations of topical bevacizumab on corneal neovascularization. Acta Ophthalmol 88: 862-867.
13. Higgins JPT, &, Green S, eds. (2011) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from http://www.cochrane-handbook.org.
14. Hos D, Saban DR, Bock F, Regenfuss B, Onderka J, Masli S, &, Cursiefen C, (2011): Suppression of inflammatory corneal lymphangiogenesis by application of topical corticosteroids. Arch Ophthalmol 129: 445-452.
15. Kim SW, Ha BJ, Kim EK, Tchah H, &, Kim TI, (2008): The effect of topical bevacizumab on corneal neovascularization. Ophthalmology 115: e33-e38.
16. Koenig Y, Bock F, Horn F, Kruse F, Straub K, &, Cursiefen C, (2009): Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 247: 1375-1382.
17. Lim M, Jacobs DS, Rosenthal P, &, Carrasquillo KG, (2009): The Boston Ocular Surface Prosthesis as a novel drug delivery system for bevacizumab. Semin Ophthalmol 24: 149-155.
18. Nakao S, Hata Y, Miura M, et al., (2007): Dexamethasone inhibits interleukin-1beta-induced corneal neovascularization: role of nuclear factor-kappaB-activated stromal cells in inflammatory angiogenesis. Am J Pathol 171: 1058-1065.
19. Papathanassiou M, Theodossiadis PG, Liarakos VS, Rouvas A, Giamarellos-Bourboulis EJ, &, Vergados IA, (2008): Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model. Am J Ophthalmol 145: 424-431.
20. Proia AD, Hirakata A, McInnes JS, Scroggs MW, &, Parikh I, (1993): The effect of angiostatic steroids and beta-cyclodextrin tetradecasulfate on corneal neovascularization in the rat. Exp Eye Res 57: 693-698.
21. Qian CX, Bahar I, Levinger E, &, Rootman D, (2008): Combined use of superficial keratectomy and subconjunctival bevacizumab injection for corneal neovascularization. Cornea 27: 1090-1092.
22. Regenfuss B, Bock F, Bachmann B, Konig Y, Hos D, Parthasarathy A, &, Cursiefen C, (2009): Topical inhibition of angiogenesis at the cornea. Safety and efficacy. Ophthalmologe 106: 399-406.
23. Sholley MM, Ferguson GP, Seibel HR, Montour JL, &, Wilson JD, (1984): Mechanisms of neovascularization. Vascular sprouting can occur without proliferation of endothelial cells. Lab Invest 51: 624-634.
24. Uy HS, Chan PS, &, Ang RE, (2008): Topical bevacizumab and ocular surface neovascularization in patients with stevens-johnson syndrome. Cornea 27: 70-73.
25. Whitcher JP, Srinivasan M, &, Upadhyay MP, (2002): Prevention of corneal ulceration in the developing world. Int Ophthalmol Clin 42: 71-77.
26. You IC, Kang IS, Lee SH, &, Yoon KC, (2009): Therapeutic effect of subconjunctival injection of bevacizumab in the treatment of corneal neovascularization. Acta Ophthalmol 87: 653-658.
27. Zaki AA, &, Farid SF, (2010): Subconjunctival bevacizumab for corneal neovascularization. Acta Ophthalmol 88: 868-871.